MCID: BRS049
MIFTS: 56

Breast Carcinoma in Situ

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Breast Carcinoma in Situ

MalaCards integrated aliases for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 45 15
Non-Infiltrating Carcinoma of Breast 12
Carcinoma in Situ of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD9CM 36 233.0
MeSH 45 D000071960
ICD10 34 D05 D05.9
UMLS 74 C0154084

Summaries for Breast Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the breast.

MalaCards based summary : Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to comedo carcinoma and lobular neoplasia. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Sodium Citrate and Anastrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.5 ERBB2 ESR1
2 lobular neoplasia 32.0 BRCA1 ERBB2 ESR1
3 ductal carcinoma in situ 30.5 BRCA1 BRCA2 ERBB2 ESR1 KRT5 PGR
4 in situ carcinoma 29.9 BRCA1 ERBB2 ESR1 KRT5 PGR TP53
5 breast ductal carcinoma 29.2 BRCA1 ERBB2 ESR1 MET PGR TP53
6 female breast cancer 28.9 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
7 ovarian cancer 28.4 BRCA1 BRCA2 ERBB2 ESR1 KDR PGR
8 breast cancer 26.3 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
9 breast apocrine carcinoma in situ 11.9
10 breast-ovarian cancer, familial 1 10.5 BRCA1 BRCA2
11 pleomorphic adenoma carcinoma 10.5 ERBB2 TP53
12 hereditary site-specific ovarian cancer syndrome 10.5 BRCA1 BRCA2
13 infiltrating angiolipoma 10.5 VEGFA VEGFC
14 gorham's disease 10.4 FLT4 VEGFC
15 congenital lymphedema 10.4 FLT4 VEGFC
16 glomeruloid hemangioma 10.4 FLT1 VEGFA
17 tuberculous salpingitis 10.4 BRCA1 BRCA2 ERBB2
18 fallopian tube adenocarcinoma 10.4 BRCA1 BRCA2 ERBB2
19 critical limb ischemia 10.4 IL6 VEGFA
20 uterine corpus serous adenocarcinoma 10.4 BRCA1 ERBB2 TP53
21 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
22 keratinizing squamous cell carcinoma 10.3 KRT5 TP53
23 mutagen sensitivity 10.3 BRCA1 BRCA2 TP53
24 breast reconstruction 10.3 BRCA1 BRCA2
25 hereditary breast ovarian cancer syndrome 10.3 BRCA1 BRCA2 TP53
26 hemifacial spasm 10.2 FLT4 VEGFA
27 respiratory system disease 10.2 IL6 TP53 VEGFA
28 male reproductive system disease 10.2 IL6 TP53 VEGFA
29 lymphangiosarcoma 10.2 FLT4 VEGFA VEGFC
30 supratentorial cancer 10.2 KDR TP53 VEGFA
31 cerebrum cancer 10.2 KDR TP53 VEGFA
32 angiokeratoma circumscriptum 10.2 FLT1 KDR VEGFA
33 brain cancer 10.2 BRCA2 KDR TP53 VEGFA
34 skin hemangioma 10.2 FLT1 KDR VEGFA
35 stomach disease 10.2 ERBB2 MET TP53 VEGFA
36 epithelioid hemangioendothelioma 10.2 FLT1 KDR VEGFA
37 peritoneum cancer 10.2 BRCA1 BRCA2 KRT5
38 capillary hemangioma 10.2 FLT1 KDR VEGFA
39 breast squamous cell carcinoma 10.2 ERBB2 KRT5 TP53
40 progesterone-receptor negative breast cancer 10.2 ERBB2 PGR
41 breast cystic hypersecretory carcinoma 10.2 ERBB2 KRT5
42 breast malignant phyllodes tumor 10.2 PGR TP53
43 primary effusion lymphoma 10.2 IL6 MET VEGFA
44 li-fraumeni syndrome 10.2 BRCA1 BRCA2 TP53
45 differentiated thyroid carcinoma 10.2 MET TP53 VEGFA
46 osteoporotic fracture 10.2 ESR1 IL6
47 corneal neovascularization 10.1 FLT1 KDR VEGFA
48 tonsil cancer 10.1 ERBB2 KRT5 TP53
49 placental insufficiency 10.1 FLT1 KDR VEGFA
50 retinal vascular disease 10.1 FLT1 KDR VEGFA

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to Breast Carcinoma in Situ

Symptoms & Phenotypes for Breast Carcinoma in Situ

GenomeRNAi Phenotypes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

27 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.68 ESR1 FGFR1 KDR
2 Decreased viability GR00221-A-2 9.68 BRCA1 ESR1 FGFR1 FLT1 FLT4 KDR
3 Decreased viability GR00221-A-3 9.68 BRCA1 KDR
4 Decreased viability GR00221-A-4 9.68 ESR1 KDR
5 Decreased viability GR00301-A 9.68 BRCA1
6 Decreased viability GR00342-S-1 9.68 FLT4
7 Decreased viability GR00342-S-2 9.68 FLT4
8 Decreased viability GR00342-S-3 9.68 FLT4
9 Decreased viability GR00402-S-2 9.68 BRCA1 ESR1 FGFR1 FLT1 FLT4 KDR
10 Decreased substrate adherent cell growth GR00193-A-1 9.35 MET
11 Decreased substrate adherent cell growth GR00193-A-3 9.35 MET
12 Decreased substrate adherent cell growth GR00193-A-4 9.35 FGFR1 KDR MET

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.52 BRCA1 ERBB2 ESR1 FGFR1 FLT1 FLT4
2 cellular MP:0005384 10.49 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
3 growth/size/body region MP:0005378 10.48 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
4 behavior/neurological MP:0005386 10.47 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
5 embryo MP:0005380 10.47 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
6 homeostasis/metabolism MP:0005376 10.46 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
7 mortality/aging MP:0010768 10.45 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
8 digestive/alimentary MP:0005381 10.44 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
9 immune system MP:0005387 10.42 BRCA1 BRCA2 ESR1 FGFR1 FLT1 FLT4
10 integument MP:0010771 10.41 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
11 endocrine/exocrine gland MP:0005379 10.4 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
12 hematopoietic system MP:0005397 10.35 BRCA1 BRCA2 ESR1 FGFR1 FLT1 IL6
13 muscle MP:0005369 10.29 BRCA1 ERBB2 ESR1 FGFR1 FLT1 FLT4
14 nervous system MP:0003631 10.28 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
15 limbs/digits/tail MP:0005371 10.26 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6ST
16 normal MP:0002873 10.21 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
17 neoplasm MP:0002006 10.2 BRCA1 BRCA2 ERBB2 ESR1 IL6 IL6ST
18 liver/biliary system MP:0005370 10.16 ESR1 FLT4 IL6 IL6ST KDR LIF
19 craniofacial MP:0005382 10.15 ERBB2 FGFR1 KDR KRT5 MET TP53
20 adipose tissue MP:0005375 10.1 BRCA1 ESR1 FLT4 IL6 LIF TP53
21 no phenotypic analysis MP:0003012 10.1 ESR1 FGFR1 FLT4 KDR KRT19 KRT5
22 reproductive system MP:0005389 10.1 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
23 renal/urinary system MP:0005367 9.87 BRCA1 ESR1 FGFR1 IL6 MET TP53
24 respiratory system MP:0005388 9.81 BRCA1 ERBB2 ESR1 IL6 KDR LIF
25 skeleton MP:0005390 9.77 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
26 vision/eye MP:0005391 9.28 FGFR1 FLT1 IL6 IL6ST KDR LIF

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
2
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
3
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
4
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
5
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
6
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
7
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
8 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Citrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Chelating Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable
23 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24
Trastuzumab Approved, Investigational Phase 3,Phase 2,Not Applicable 180288-69-1 9903
25
Progesterone Approved, Vet_approved Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
26
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
27
Polyestradiol phosphate Approved Phase 3,Phase 2 28014-46-2
28
Norethindrone Approved Phase 3 68-22-4 6230
29
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
30
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
31
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
32
Metformin Approved Phase 3,Phase 1 657-24-9 14219 4091
33
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
34
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
35 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
36 Antineoplastic Agents, Immunological Phase 3,Phase 2,Not Applicable,Early Phase 1
37 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
38 Contraceptive Agents Phase 3,Early Phase 1
39 Contraceptives, Oral Phase 3,Early Phase 1
40 Norethindrone Acetate Phase 3
41 Estradiol 17 beta-cypionate Phase 3,Phase 2
42 Estradiol 3-benzoate Phase 3,Phase 2
43
Medroxyprogesterone Phase 3 520-85-4 10631
44 Contraceptive Agents, Male Phase 3
45 Anti-Allergic Agents Phase 3
46 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Dermatologic Agents Phase 3,Phase 2
48 Estrogens, Conjugated (USP) Phase 3,Phase 2
49 Anesthetics, General Phase 3
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 249)
# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
4 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
5 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
6 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
7 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
8 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
9 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
10 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
11 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
14 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
15 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
16 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
17 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
18 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
19 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
20 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
21 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
22 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
23 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
24 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation Active, not recruiting NCT00673335 Phase 3 letrozole;Placebo
25 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
26 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
27 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
28 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
29 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
30 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
31 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
32 Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer Completed NCT02556632 Phase 2 Curcumin-based Gel
33 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed NCT01439711 Phase 2 letrozole
34 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Completed NCT02150525 Phase 2
35 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
36 Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Completed NCT01869764 Phase 2
37 Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer Completed NCT00084539 Phase 2
38 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy Completed NCT00843167 Phase 2
39 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
40 Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease Completed NCT00031720 Phase 2 Tamoxifen
41 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
42 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Completed NCT00354640 Phase 2 anastrozole;simvastatin
43 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Completed NCT00764322 Phase 2 tamoxifen citrate
44 Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer Completed NCT00244959 Phase 2 anastrozole
45 Letrozole in Preventing Breast Cancer in Postmenopausal Women Completed NCT00090857 Phase 2 Letrozole
46 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
47 Treatment With Pazopanib for Neoadjuvant Breast Cancer Completed NCT00849472 Phase 2 doxorubicin + cyclophosphamide;paclitaxel + pazopanib;pazopanib monotherapy
48 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
49 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
50 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ Completed NCT00586326 Phase 2

Search NIH Clinical Center for Breast Carcinoma in Situ

Cochrane evidence based reviews: breast carcinoma in situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

MalaCards organs/tissues related to Breast Carcinoma in Situ:

42
Breast, Skin, Bone, Lymph Node, Testes, Prostate, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Carcinoma in Situ:

20
The Breast

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show all 47)
# Title Authors Year
1
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. ( 29513252 )
2018
2
Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years. ( 30025999 )
2018
3
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. ( 28286675 )
2017
4
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. ( 27926499 )
2016
5
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. ( 27639877 )
2016
6
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. ( 26062614 )
2015
7
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. ( 22595929 )
2012
8
Differences in breast carcinoma in situ between menopausal and premenopausal women. ( 21617240 )
2011
9
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. ( 21149333 )
2010
10
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? ( 19896281 )
2010
11
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. ( 20565829 )
2010
12
Prevalence of breast carcinoma in situ in the United States. ( 19706857 )
2009
13
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). ( 18317962 )
2008
14
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. ( 18665169 )
2008
15
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. ( 17063272 )
2007
16
Cigarette smoking and risk of breast carcinoma in situ. ( 17700252 )
2007
17
Oral contraceptive use and risk of breast carcinoma in situ. ( 18006914 )
2007
18
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. ( 17244359 )
2007
19
Quality of life for women diagnosed with breast carcinoma in situ. ( 17050872 )
2006
20
Oral contraceptive use and risk of breast carcinoma in situ (United States). ( 17006721 )
2006
21
Molecular classification of breast carcinoma in situ. ( 17375183 )
2006
22
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. ( 15540225 )
2005
23
Impact of reproductive factors and lactation on breast carcinoma in situ risk. ( 15054874 )
2004
24
Lifetime recreational exercise activity and risk of breast carcinoma in situ. ( 14601085 )
2003
25
Oral contraceptives and the risk of ductal breast carcinoma in situ. ( 14572155 )
2003
26
Proliferative lesions of the breast: carcinoma in situ. ( 15022899 )
2003
27
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. ( 14659121 )
2003
28
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. ( 12611452 )
2003
29
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. ( 12670886 )
2003
30
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. ( 12118344 )
2002
31
Breast carcinoma in situ: risk factors and screening patterns. ( 11734598 )
2001
32
Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. ( 11444192 )
2001
33
Risk of subsequent invasive breast cancer after breast carcinoma in situ. ( 10703809 )
2000
34
p53 mutations and expression in breast carcinoma in situ. ( 10623666 )
2000
35
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. ( 9622698 )
1998
36
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. ( 9071907 )
1997
37
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. ( 8692711 )
1996
38
Biological heterogeneity of breast carcinoma in situ. ( 8651598 )
1996
39
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. ( 7654052 )
1995
40
Breast carcinoma-in-situ: an emerging problem in Singapore. ( 1329232 )
1992
41
Breast carcinoma in situ. ( 20169700 )
1992
42
Receptors for estrogen and progesterone in breast carcinoma in situ. ( 1295456 )
1992
43
Ten-year follow-up of breast carcinoma in situ in Connecticut. ( 1365682 )
1992
44
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. ( 1657650 )
1991
45
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. ( 1677296 )
1991
46
Breast carcinoma in situ. ( 2535929 )
1989
47
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. ( 2990246 )
1985

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 ERBB2 ESR1 FGFR1 FLT1 FLT4 IL6
2
Show member pathways
13.91 ERBB2 FGFR1 FLT1 FLT4 IL6 IL6ST
3
Show member pathways
13.89 BRCA1 ERBB2 ESR1 FGFR1 FLT1 FLT4
4
Show member pathways
13.73 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
5
Show member pathways
13.72 ERBB2 FGFR1 FLT1 FLT4 IL6 IL6ST
6
Show member pathways
13.59 BRCA1 ERBB2 FGFR1 FLT1 FLT4 IL6
7
Show member pathways
13.58 ERBB2 FGFR1 FLT1 FLT4 IL6 KDR
8
Show member pathways
13.47 ERBB2 FGFR1 FLT1 FLT4 IL6 KDR
9
Show member pathways
13.41 ERBB2 FGFR1 IL6 IL6ST LIF MET
10
Show member pathways
13.37 ERBB2 FGFR1 FLT1 FLT4 IL6 KDR
11
Show member pathways
13.37 ERBB2 FGFR1 FLT1 FLT4 IL6 KDR
12
Show member pathways
13.35 ERBB2 ESR1 FGFR1 FLT1 FLT4 IL6
13
Show member pathways
13.14 FGFR1 FLT1 FLT4 IL6 KDR MET
14
Show member pathways
13.1 FGFR1 FLT1 FLT4 IL6 KDR MET
15
Show member pathways
13.03 ERBB2 FGFR1 FLT1 FLT4 KDR MET
16
Show member pathways
12.97 ERBB2 FLT1 FLT4 KDR MET VEGFA
17
Show member pathways
12.89 BRCA2 ERBB2 FGFR1 TP53 VEGFA
18
Show member pathways
12.88 ERBB2 FGFR1 IL6 IL6ST LIF
19
Show member pathways
12.82 FGFR1 FLT1 FLT4 KDR MET VEGFA
20
Show member pathways
12.8 FGFR1 FLT1 FLT4 IL6 KDR MET
21 12.78 ERBB2 FGFR1 FLT1 FLT4 KDR MET
22
Show member pathways
12.75 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
23
Show member pathways
12.66 FLT1 FLT4 KDR VEGFA VEGFC
24
Show member pathways
12.61 ERBB2 MET TP53 VEGFA
25
Show member pathways
12.6 ERBB2 FGFR1 FLT1 FLT4 KDR MET
26 12.58 BRCA1 ERBB2 MET TP53 VEGFA
27
Show member pathways
12.53 ERBB2 FGFR1 FLT1 FLT4 KDR MET
28
Show member pathways
12.53 BRCA1 ERBB2 FGFR1 FLT1 FLT4 IL6
29
Show member pathways
12.48 FLT1 FLT4 KDR VEGFA VEGFC
30
Show member pathways
12.48 ERBB2 FGFR1 FLT1 FLT4 IL6 KDR
31
Show member pathways
12.48 FGFR1 FLT1 FLT4 KDR MET VEGFA
32
Show member pathways
12.45 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
33
Show member pathways
12.43 BRCA1 ESR1 KDR VEGFA
34 12.36 ERBB2 ESR1 FGFR1 KDR MET TP53
35
Show member pathways
12.32 FGFR1 FLT1 KDR VEGFA VEGFC
36 12.29 FLT1 IL6 MET TP53
37
Show member pathways
12.29 FGFR1 FLT1 FLT4 IL6 KDR MET
38 12.24 BRCA1 BRCA2 ESR1 TP53 VEGFA
39 12.18 IL6 KDR KRT19 LIF MET VEGFA
40
Show member pathways
12.14 BRCA1 FGFR1 FLT1 FLT4 IL6 KDR
41
Show member pathways
12.11 ERBB2 FGFR1 FLT1 FLT4 IL6ST KDR
42 12.1 FLT1 KDR TP53 VEGFA
43 12.09 BRCA2 ERBB2 ESR1 FGFR1 FLT4 IL6
44 12.08 ERBB2 FGFR1 FLT1 FLT4 KDR MET
45 12.06 IL6 LIF TP53 VEGFA
46 12.01 ERBB2 FGFR1 FLT1 FLT4 IL6ST KDR
47 11.98 ERBB2 FLT1 IL6 VEGFA
48
Show member pathways
11.98 FLT1 FLT4 KDR VEGFA VEGFC
49 11.96 IL6 IL6ST TP53
50 11.96 FGFR1 FLT1 FLT4 KDR VEGFC

GO Terms for Breast Carcinoma in Situ

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 FGFR1 FLT1 FLT4 IL6 IL6ST KDR
2 lateral element GO:0000800 9.32 BRCA1 BRCA2
3 receptor complex GO:0043235 9.17 ERBB2 FGFR1 FLT1 FLT4 IL6ST KDR
4 interleukin-6 receptor complex GO:0005896 9.16 IL6 IL6ST
5 cytoplasm GO:0005737 10.03 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.98 ERBB2 FLT4 KDR VEGFA VEGFC
2 positive regulation of protein kinase B signaling GO:0051897 9.97 ERBB2 ESR1 FGFR1 MET
3 angiogenesis GO:0001525 9.97 FGFR1 FLT1 FLT4 KDR VEGFA VEGFC
4 protein autophosphorylation GO:0046777 9.95 ERBB2 FGFR1 FLT1 FLT4 KDR
5 phosphatidylinositol phosphorylation GO:0046854 9.93 ERBB2 ESR1 FGFR1 MET
6 positive regulation of angiogenesis GO:0045766 9.93 BRCA1 FLT1 KDR VEGFA VEGFC
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.92 IL6 LIF TP53 VEGFA
8 positive regulation of cell proliferation GO:0008284 9.91 FGFR1 FLT1 FLT4 IL6 IL6ST KDR
9 positive regulation of endothelial cell proliferation GO:0001938 9.9 FLT4 KDR VEGFA VEGFC
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IL6 IL6ST LIF VEGFA
11 lung development GO:0030324 9.88 FGFR1 LIF VEGFA
12 positive regulation of MAP kinase activity GO:0043406 9.88 ERBB2 FGFR1 FLT1 VEGFA
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.87 IL6 LIF VEGFA
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 FGFR1 FLT1 KDR
15 response to estrogen GO:0043627 9.86 BRCA1 ESR1 KRT19
16 positive regulation of epithelial cell proliferation GO:0050679 9.86 ERBB2 VEGFA VEGFC
17 positive regulation of endothelial cell migration GO:0010595 9.85 FLT4 KDR VEGFA
18 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.85 ERBB2 FLT1 FLT4 KDR MET
19 peptidyl-tyrosine phosphorylation GO:0018108 9.85 ERBB2 FGFR1 FLT1 FLT4 KDR MET
20 positive chemotaxis GO:0050918 9.84 MET VEGFA VEGFC
21 lung alveolus development GO:0048286 9.83 FLT4 LIF PGR
22 positive regulation of blood vessel endothelial cell migration GO:0043536 9.83 FGFR1 KDR VEGFA VEGFC
23 cell differentiation GO:0030154 9.83 FLT1 KDR TP53 VEGFA VEGFC
24 sprouting angiogenesis GO:0002040 9.82 FLT4 VEGFA VEGFC
25 blood vessel morphogenesis GO:0048514 9.81 FGFR1 FLT1 FLT4
26 positive regulation of vascular endothelial growth factor production GO:0010575 9.8 BRCA1 FLT4 IL6ST
27 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.78 FLT1 FLT4 KDR VEGFA
28 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.74 BRCA1 BRCA2 TP53
29 positive regulation of phospholipase C activity GO:0010863 9.73 ESR1 FGFR1 FLT1
30 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.72 FLT1 FLT4 KDR VEGFA VEGFC
31 interleukin-6-mediated signaling pathway GO:0070102 9.71 IL6 IL6ST
32 induction of positive chemotaxis GO:0050930 9.71 VEGFA VEGFC
33 positive regulation of acute inflammatory response GO:0002675 9.7 IL6 IL6ST
34 positive regulation of astrocyte differentiation GO:0048711 9.7 IL6ST LIF
35 positive regulation of positive chemotaxis GO:0050927 9.7 KDR VEGFA
36 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.69 ESR1 TP53
37 positive regulation of protein kinase C signaling GO:0090037 9.69 FLT4 VEGFA
38 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.69 FLT1 FLT4 KDR
39 positive regulation of mast cell chemotaxis GO:0060754 9.68 VEGFA VEGFC
40 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.67 KDR VEGFA
41 leukemia inhibitory factor signaling pathway GO:0048861 9.66 IL6ST LIF
42 negative regulation of apoptotic process GO:0043066 9.63 FLT4 IL6 IL6ST KDR TP53 VEGFA
43 chordate embryonic development GO:0043009 9.58 BRCA1 BRCA2 FGFR1
44 vascular endothelial growth factor signaling pathway GO:0038084 9.35 FLT1 FLT4 KDR VEGFA VEGFC
45 positive regulation of MAPK cascade GO:0043410 9.17 ERBB2 FGFR1 FLT1 FLT4 IL6 KDR
46 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 BRCA1 ESR1 IL6 LIF MET PGR
47 phosphorylation GO:0016310 10.15 ERBB2 FGFR1 FLT1 FLT4 KDR MET
48 protein phosphorylation GO:0006468 10.13 ERBB2 FGFR1 FLT1 FLT4 KDR MET
49 positive regulation of gene expression GO:0010628 10.08 BRCA1 ERBB2 IL6 LIF TP53 VEGFA
50 cytokine-mediated signaling pathway GO:0019221 10.04 IL6 IL6ST LIF TP53 VEGFA

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.99 ERBB2 FGFR1 FLT1 FLT4 KDR MET
2 protein kinase activity GO:0004672 9.95 ERBB2 FGFR1 FLT1 FLT4 KDR MET
3 identical protein binding GO:0042802 9.85 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 KDR
4 growth factor activity GO:0008083 9.8 IL6 LIF VEGFA VEGFC
5 protein phosphatase binding GO:0019903 9.76 ERBB2 FLT4 MET TP53
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.73 ERBB2 ESR1 FGFR1 MET
7 protein tyrosine kinase activity GO:0004713 9.73 ERBB2 FGFR1 FLT1 FLT4 KDR MET
8 interleukin-6 receptor binding GO:0005138 9.54 IL6 IL6ST
9 vascular endothelial growth factor-activated receptor activity GO:0005021 9.54 FLT1 FLT4 KDR
10 growth factor binding GO:0019838 9.35 ERBB2 FLT1 FLT4 IL6ST KDR
11 vascular endothelial growth factor receptor 3 binding GO:0043185 9.22 VEGFC
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.1 ERBB2 FGFR1 FLT1 FLT4 KDR MET
13 transmembrane signaling receptor activity GO:0004888 9.02 ERBB2
14 protein binding GO:0005515 10.36 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
15 ATP binding GO:0005524 10.09 ERBB2 FGFR1 FLT1 FLT4 KDR MET

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....